An oxygen-generating implant keeps high-density insulin-producing cells alive in diabetic rats for months without immune suppression.

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.